

CANCER CONSULTANTS OF AMERICA

BRIDGING THE GAP BETWEEN CANCER AND UNDERSTANDING®

Cancer Answers

Ivermectin as a Cancer Treatment

Prior to the year 2020, a small population of people has ever heard of Ivermectin. This anti-parasitic drug was commonly used as a dewormer medication for animals plagued with gastrointestinal worms. However, this drug gained popularity during a memorable moment in human history, the COVID-19 pandemic. Ivermectin was found to directly target COVID-19 and subsequently prevent entry of the virus into the host cell. Additionally, it has been reported that ivermectin prevents viral replication and assembly within the cell. Since this drug was thrusted into the spotlight, more information has been gained about the therapeutic benefits of ivermectin. Notably, it was discovered to be effective at inhibiting the rate of accelerated growth seen for certain cancers.

Ivermectin was discovered in the early 1970's by Japanese scientist, Satoshi Omura, who received the 2015 Nobel Prize in Physiology and Medicine along with his collaborator William Campbell for their work showing the effectiveness as an anti-parasitic drug. Since its discovery, ivermectin has been investigated and recognized for the therapeutic benefits it displays when treating several medical conditions, including cancer. Numerous reports are available detailing how ivermectin inhibits multiple cellular pathways that are utilized by cancer cells under laboratory conditions. In a 2022 report, ivermectin was found to inhibit cancer cell cycle progression, a vital cellular process that allows cancer cells to rapidly multiply. Furthermore, at low doses the drug was found to induce apoptosis, programmed cell death, resulting in the death of the cancer cells following the ivermectin treatments.

Ivermectin has been shown to be effective at stopping the cellular proliferation of many types of cancer. Several mechanisms of action have been reported that describe

(continued next column)

how ivermectin inhibits well-established cellular pathways that promote cancer proliferation. For instance, ivermectin targets PAK1, a key enzyme for cancer development. Following ivermectin treatment PAK1 was reported to be degraded within the cancer cell resulting in the cancer cell's inability to divide and produce more cancer cells. Although this is just one pathway described for ivermectin as a therapeutic drug, more pathways have been reported for other types of cancer including breast cancer, leukemia, skin cancer melanoma, ovarian cancer, and lung cancer. At this time, ivermectin is not approved by the U.S. FDA for the treatment of COVID-19. Additionally, despite numerous clinical trials investigating ivermectin for the treatment of cancer, it remains to be approved by this same agency. Taken together, more research is needed to establish safety and efficacy of this popular drug that was discovered in Japan more than 50 years ago.

Submit your Cancer Answers topics to info@CancerConsultantsOfAmerica.com

We Are Available to You

Please contact us today if you would like more information about how our services can benefit you and your family.

Services:

- Individual and Family Cancer Education
- Medical Appointment Liaison Services
- Information Seminars and Public Speaking Events

Fun Facts – March

Cancer Awareness Month:

- Colorectal Cancer (Dark Blue)
- Anal Cancer (Purple/Green)
- Kidney Cancer (Orange)
- Myeloma (Burgundy)









March 1 – Share A Smile Day

March 4 – Pancake Day

March 13 – National Good Samaritan Day 🙉

March 15 – National Napping Day

March 17 – St. Patrick's Day

March 23 – World Meteorological Day



@cancer_america



@cancer_america



@cancer_america



@cancer.america

March 2025

Cancer Consultants Of America

Phone: (561) 252-3090

E-mail: info@CancerConsultantsOfAmerica.com

www.CancerConsultantsOfAmerica.com

© 2025 Cancer Consultants Of America